233 related articles for article (PubMed ID: 28589491)
1. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.
Bartucci M; Hussein MS; Huselid E; Flaherty K; Patrizii M; Laddha SV; Kui C; Bigos RA; Gilleran JA; El Ansary MMS; Awad MAM; Kimball SD; Augeri DJ; Sabaawy HE
Target Oncol; 2017 Aug; 12(4):449-462. PubMed ID: 28589491
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules.
Yang T; Chen Y; Zhao P; Xue H; You J; Li B; Liu Y; He C; Zhang X; Fan L; Lee RJ; Li L; Ma X; Xu C; Xiang G
Nanomedicine; 2018 Oct; 14(7):2009-2021. PubMed ID: 29842934
[TBL] [Abstract][Full Text] [Related]
3. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G
Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848
[TBL] [Abstract][Full Text] [Related]
4. Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.
Zhang R; Xu LB; Yue XJ; Yu XH; Wang J; Liu C
Oncol Rep; 2013 Mar; 29(3):967-74. PubMed ID: 23242307
[TBL] [Abstract][Full Text] [Related]
5. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.
Wu WR; Sun H; Zhang R; Yu XH; Shi XD; Zhu MS; Zeng H; Yan LX; Xu LB; Liu C
Oncotarget; 2016 Apr; 7(14):18684-93. PubMed ID: 26919246
[TBL] [Abstract][Full Text] [Related]
6. Ethyl acetate extract from Jiedu Xiaozheng Yin inhibits the proliferation of human hepatocellular carcinoma cells by suppressing polycomb gene product Bmi1 and Wnt/β-catenin signaling.
Chen XZ; Cao ZY; Li JN; Hu HX; Zhang YQ; Huang YM; Liu ZZ; Hu D; Liao LM; Du J
Oncol Rep; 2014 Dec; 32(6):2710-8. PubMed ID: 25333742
[TBL] [Abstract][Full Text] [Related]
7. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma.
Chiba T; Miyagi S; Saraya A; Aoki R; Seki A; Morita Y; Yonemitsu Y; Yokosuka O; Taniguchi H; Nakauchi H; Iwama A
Cancer Res; 2008 Oct; 68(19):7742-9. PubMed ID: 18829528
[TBL] [Abstract][Full Text] [Related]
8. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
9. Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice.
Qi S; Li B; Yang T; Liu Y; Cao S; He X; Zhang P; Li L; Xu C
Int J Mol Sci; 2014 Nov; 15(11):20004-21. PubMed ID: 25372945
[TBL] [Abstract][Full Text] [Related]
10. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
11. Identification of BMI1 Promoter Inhibitors from Beaumontia murtonii and Eugenia operculata.
Kaneta Y; Arai MA; Ishikawa N; Toume K; Koyano T; Kowithayakorn T; Chiba T; Iwama A; Ishibashi M
J Nat Prod; 2017 Jun; 80(6):1853-1859. PubMed ID: 28598616
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
Yamashita T; Honda M; Nio K; Nakamoto Y; Yamashita T; Takamura H; Tani T; Zen Y; Kaneko S
Cancer Res; 2010 Jun; 70(11):4687-97. PubMed ID: 20484035
[TBL] [Abstract][Full Text] [Related]
14. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Bmi‑1 promotes epithelial‑mesenchymal transition in CD133+Hep G2 cells.
Zhang Z; Wang Q; Bu X; Zhang C; Chen H; Sha W; Liu W
Mol Med Rep; 2017 Nov; 16(5):6156-6161. PubMed ID: 28849237
[TBL] [Abstract][Full Text] [Related]
16. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
[TBL] [Abstract][Full Text] [Related]
17. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
18. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
19. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
